The Journey Of Eric Lefkofsky In Cancer Treatment

Eric Paul Lefkofsky is one of the prominent entrepreneurs in America known for his outstanding establishments.He is the C.E.O of Tempus, Groupon, founding partner of Lightbank, a co-founder of uptake technologies, Mediaocean and Inner workings.

Statistics in the United States have shown that almost 40 percent of the adults have cancer; 14.5 million in 2014 had cancer. In 2024 the number is expected to rise to 19 million according to statistics.

When Liz, the wife of Lefkofsky, got diagnosed with breast cancer he had a traumatic experience as it was his first time to be up close with a cancer patient. It was at this time he came to know that the data gathered and digital technology used to treat the patients was not effective. He established Tempus to deal with such issues and provide better services to cancer patients.

Tempus came into existence to ensure patients with cancer get treatment which is efficient and suitable. The company’ objective is to change the way therapy was administered, change cancer care delivery methods and to analyze molecular and clinical data of cancer patients.

Tempus Company which is the forefront of data-enabled precision medicine offers a more defined treatment to patients who get diagnosed with cancer. Doctors have benefited from this platform findings; they can make better decisions for their patients and give them the right prescriptions.

Through Tempus the genome sequencing is now affordable and will contribute handsomely to the data enabled precise medicine project. Lefkofsky and wife Liz have been donating funds through the Lefkofsky Family Foundation that they established in 2006, to ensure the lives of the communities is improved and also support the universities in their cancer research programs. Lefkofsky has achieved numerous things in his life including being a trustee member at Lurie’s Children Memorial Hospital, The Art Institute of Chicago and Chicago Steppenwolf Theatre Company.

He also serves as an assistant professor at the University of Chicago and continues to accumulate his teaching career. He graduated from the University of Michigan and received his Juris Doctor at the Law School of Michigan University.
Eric Believes that in future data enabled medicine will be able to treat not only cancer but also other many diseases efficiently.

Eric Lefkofsky Facebook Page:

How Clay Siegall Brought Seattle Genetics To The Forefront Of ADS Celelopment

In an exclusive interview posted on Inspirery, Dr. Clay Siegall, the CEO of Seattle Genetics, explains why he has focused on targeted therapies for cancer. Siegall, who holds a PhD in genetics from George Washington University, co-founded the biotech company to update cancer treatments so that chemotherapy is not so traumatic for cancer patients. Since Seattle Genetics’ first ADC, which targets cancer cells as opposed to both cancer and healthy cells, became FDA-approved, Siegall has generated substantial revenue for company by arranging licensing agreements. They took a risk, said Siegall, since only one out of every ten drugs submitted to the FDA receives their approval. Under Siegall’s leadership, Seattle Genetics is developing a diverse pipeline of ADCs to treat various types of cancer.


When ideamensh interviewed Siegall, he said that his drive came from a desire to help cancer patients because, when he was 19 years old, Siegall saw first hand how few tools oncologists had to treat cancer. He has held positions at the National Institutes of Health and the National Cancer Institute before joining Bristol-Myers Squibb Pharmaceutical Research Institute, which brought Siegall to the Seattle area.


In addition to serving as Seattle Genetics’ CEO, Siegall is the president of the biotechnology company and the chairman of the board. He also lends his extensive pharmaceutical industry experience to the Boards of Directors of Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, Mirna Therapeutics and Washington Roundtable.


Siegall has stated that Seattle Genetics will focus on proprietary antibody-drug conjugates (ADCs) development; the company wholly owns new ADCs. While Seattle Genetics has collaborated with Abbott, Pfizer, Bayer and other companies, Siegall says, “We will continue to see a lot of partnering, but because we’re a much bigger, stronger company, we’re going to probably spend most of the time developing drugs on our own.”